Screening Brain MRIs in Patients with Stage IV Breast Cancer

Inclusion Criteria

• Histologic diagnosis of breast cancer with documentation of estrogen receptor(ER)/progesterone receptor (PR)/HER2 status.
• Radiographic evidence of stage IV extracranial disease having progressed past first line therapy in hormone receptor (HR)+/HER2- patients.
• Radiographic evidence of stage IV extracranial disease in triple negative (TN) and HER2+ patients.
• Age >= 18.
• Life expectancy >= 6 months.
• Eastern Cooperative Oncology Group performance status 0 to 2
• Patients must be able to understand and the willingness to sign an informed consent for study procedures.
• Stated willingness to comply with all study procedures and availability for the duration of the study.

Exclusion Criteria

• Prior diagnosis or treatment of brain metastases or leptomeningeal disease.
• Patients with prior history of non-breast cancer malignancies should be no evidence of disease (NED) >= 2 years with the exception of those with a negligible risk of metastasis or death (e.g., 5-year overall survival [OS] of > 90%), such as but not limited to, non-melanoma skin carcinoma, stage I endometrioid uterine cancer, and others at the discretion of the principal investigator (PI).
• Neurologic symptoms warranting standard screening brain MRI in the judgement of the treating physician at time of enrollment.
• Indications warranting brain MRI for other neurologic conditions at time of study entry.
• Contraindication towards magnetic resonance imaging (MRI) imaging with contrast.
• Chronic kidney disease stage IV or V or end stage renal disease (CrCl <30 ml/min).